Potentially, receptor-homing peptides could be used to deliver molecules neutralizing CD36 complex transport function and signaling specifically in WAT, hepatocytes, or other cells for the treatment of obesity, hepatosteatosis, type-2 diabetes, and metastatic disease. Here, CD36 is linked to obesity due to melanocortin 4 receptor deficiency.